RxDoctor Payments Data

Jorge Verea, MD

Internal Medicine · West New York, NJNPI 1164469540

Payments from drug & device makers

$314in general payments, 2019–2025

Across 15 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$110
  • Amgen$101
  • GSK$34
  • Lilly USA, LLC$24
  • Exact Sciences$19
  • Kowa Pharmaceuticals America, Inc.$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$30096%
  • Education$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314 in reported general payments places this provider in the 45th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$35,634
Medicare patients
83
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate46$44,869
EliquisApixaban14$10,230
Memantine Hcl ErMemantine Hcl31$5,930
Breo ElliptaFluticasone/Vilanterol15$5,599
Diclofenac Sodium178$5,063
Atorvastatin Calcium338$4,750
Losartan Potassium315$2,795
Dexlansoprazole DrDexlansoprazole13$2,338
Clobetasol Propionate11$1,744
Memantine Hcl95$1,591
Omeprazole149$1,472
Metoprolol Succinate94$1,326
Fluticasone Propionate73$1,185
Omega-3 Acid Ethyl Esters32$1,172
Rosuvastatin Calcium50$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$34$5,59915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West New York

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →